Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that ...

Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

The Fortis Life Sciences team will be presenting two posters on Friday, November 8, 2024 in the George R. Brown Convention Center, Level 1 – Exhibit Halls AB.

Precis Engineering + Architecture , an award-winning design firm with locations in Ambler, PA, and Cary, NC, has hired Veera ...

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.